Involvement of lysosomal cathepsins in the cleavage of DNA topoisomerase I during necrotic cell death

Arthritis and Rheumatism

Volumn 52, Issue 7, 2005, Pages 2133-2145

  Pacheco, Fabio J ^a,b   Servin, Jacqueline ^a   Dang, David ^a   Kim, Jim ^a   Molinaro, Christine ^a   Daniels, Tracy ^a   Brown Bryan, Terry A ^a   Imoto Egami, Mizue ^b   Casiano, Carlos A ^a  

^a LOMA LINDA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIGEN; BENZYLOXYCARBONYLVALYLALANYLASPARTYL FLUOROMETHYL KETONE; CATHEPSIN; CATHEPSIN B; CATHEPSIN D; CATHEPSIN G; CATHEPSIN H; CATHEPSIN L; DNA TOPOISOMERASE; EPITOPE; MERCURIC CHLORIDE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANTIGEN RECOGNITION; ARTICLE; CELL DEATH; CELL LYSATE; CELL STRAIN L 929; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME DEGRADATION; ENZYME LOCALIZATION; FLUORESCENCE MICROSCOPY; IMMUNE RESPONSE; IMMUNOBLOTTING; LYSOSOME; MOUSE; NONHUMAN; PRIORITY JOURNAL; SYSTEMIC SCLEROSIS;

AMINO ACID CHLOROMETHYL KETONES; ANIMALS; CATHEPSINS; CATTLE; CELL NUCLEUS; DNA TOPOISOMERASES, TYPE I; ENDOTHELIUM, VASCULAR; FIBROBLASTS; HUMANS; IMMUNOBLOTTING; L CELLS (CELL LINE); LYSOSOMES; MERCURIC CHLORIDE; MICE; NECROSIS; SCLERODERMA, SYSTEMIC; TUMOR NECROSIS FACTOR-ALPHA;

EID: 22244486026     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.21147     Document Type: Article

References (41)

1. Hu QP, Fertig N, Medsger TA Jr, Wright TM. Molecular recognition patterns of serum anti-DNA topoisomerase I antibody in systemic sclerosis. J Immunol 2004;173:2834-41.
2. Hu QP, Fertig N, Medsger TA Jr, Wright TM. Correlation of serum anti-DNA topoisomerase I antibody levels with disease severity and activity in systemic sclerosis. Arthritis Rheum 2003; 48:1363-73.
3. Douvas AS, Achten M, Tan EM. Identification of a nuclear protein (Scl-70) as a unique target of human antinuclear antibodies in scleroderma. J Biol Chem 1979;254:10514-22.
4. Guldner HH, Szostecki C, Vosberg HP, Lakomek HJ, Penner E, Bautz FA. Scl 70 autoantibodies from scleroderma patients recognize a 95 kDa protein identified as DNA topoisomerase I. Chromosoma 1986;94:132-8.
5. Shero JH, Bordwell B, Rothfield NF, Earnshaw WC. High titers of autoantibodies to topoisomerase I (Scl-70) in sera from scleroderma patients. Science 1986;23:737-40.
6. D'Arpa P, Machlin PS, Ratrie H, Rothfield NF, Cleveland DW, Earnshaw WC. cDNA cloning of human DNA topoisomerase I: catalytic activity of a 67.7-kDa carboxyl-terminal fragment. Proc Natl Acad Sci U S A 1988;85:2543-7.
7. Oriss TB, Hu PQ, Wright TM. Distinct autoreactive T cell responses to native and fragmented DNA topoisomerase I: influence of APC type and IL-2. J Immunol 2001;166:5456-63.
8. Rosen A, Casciola-Rosen L. Autoantigens as substrates for apoptotic proteases: implications for the pathogenesis of systemic autoimmune disease. Cell Death Differ 1999;6:6-12.
9. Utz PJ. Anderson P. Posttranslational protein modifications, apoptosis, and the bypass of tolerance to autoantigens [review]. Arthritis Rheum 1998;41:1152-60.
10. Casiano CA, Ochs RL, Tan EM. Distinct cleavage products of nuclear proteins in apoptosis and necrosis revealed by autoantibody probes. Cell Death Differ 1998;5:183-90.
11. Wu X, Molinaro C, Johnson N, Casiano CA. Secondary necrosis is a source of proteolytically modified forms of specific intracellular autoantigens: implications for systemic autoimmunity. Arthritis Rheum 2001;44:2642-52.
12. Casiano CA, Martin SJ, Green DR, Tan EM. Selective cleavage of nuclear autoantigens during CD95 (Fas/APO-1)-mediated T cell apoptosis. J Exp Med 1996;184:765-70.
13. Samejima K, Svingen PA, Basi GS, Kottke T, Mesner PW, Stewart L, et al. Caspase-mediated cleavage of DNA topoisomerase I at unconventional sites during apoptosis. J Biol Chem 1999;274: 4335-40.
14. Casciola-Rosen L, Andrade F, Ulanet D, Wong WB, Rosen A. Cleavage by granzyme B is strongly predictive of autoantigen status: implications for initiation of autoimmunity. J Exp Med 1999;190:815-26.
15. Zhao M, Antunes F, Eaton JW, Brunk UT. Lysosomal enzymes promote mitochondrial oxidant production, cytochrome c release and apoptosis. Eur J Biochem 2003;270:3778-86.
16. Fehrenbacher N, Gyrd-Hansen M, Poulsen B, Felbor U, Kallunki T, Boes M, et al. Sensitization to the lysosomal cell death pathway upon immortalization and transformation. Cancer Res 2004;64: 5301-10.
17. Ono K, Kim SO, Han J. Susceptibility of lysosomes to rupture is a determinant for plasma membrane disruption in tumor necrosis factor α-induced cell death. Mol Cell Biol 2003;23:665-76.
18. Foghsgaard L, Wissing D, Mauch D, Lademann U, Bastholm L, Boes M, et al. Cathepsin B acts as a dominant execution protease in tumor cell apoptosis induced by tumor necrosis factor. J Cell Biol 2001;153:999-1009.
19. Broker LE, Huisman C, Span SW, Rodriguez JA, Kruyt FA, Giaccone G. Cathepsin B mediates caspase-independent cell death induced by microtubule stabilizing agents in non-small cell lung cancer cells. Cancer Res 2004;64:27-30.
20. Stewart L, Champoux JJ. Purification of baculovirus-expressed human DNA topoisomerase I. Methods Mol Biol 1999;94:223-34.
21. Yamamoto A, Kara T, Tomoo K, Ishida T, Fujii T, Hata Y, et al. Binding mode of CA074, a specific irreversible inhibitor, to bovine cathepsin B as determined by X-ray crystal analysis of the complex. J Biochem 1997;121:974-7.
22. Vercammen D, Beyaert R, Denecker G, Goossens V, van Loo G, Declercq W, et al. Inhibition of caspases increases the sensitivity of L929 cells to necrosis mediated by tumor necrosis factor. J Exp Med 1998;187:1477-85.
23. Luschen S, Ussat S, Scherer G, Kabelitz D, Adam-Klages S. Sensitization to death receptor cytotoxicity by inhibition of Fas-associated death domain protein (FADD)/caspase signaling. J Biol Chem 2000;32:24670-78.
24. Schulze-Osthoff K, Krammer PH, Droge W. Divergent signalling via APO-1/Fas and the TNF receptor, two homologous molecules involved in physiological cell death. EMBO J 1994;13:4587-96.
25. Los M, Mozoluk M, Ferrari D, Stepczynska A, Stroh C, Renz A, et al. Activation and caspase-mediated inhibition of PARP: a molecular switch between fibroblast necrosis and apoptosis in death receptor signaling. Mol Biol Cell 2002;13:978-88.
26. Gobeil S, Boucher CC, Nadeau D, Poirier GG. Characterization of the necrotic cleavage of poly (ADP-ribose) polymerase (PARP-1): implication of lysosomal proteases. Cell Death Differ 2001;8: 588-94.
27. Goulet B, Baruch A, Moon NS, Poirier M, Sansregret LL, Erickson A, et al. A cathepsin L isoform that is devoid of a signal peptide localizes to the nucleus in S phase and processes the CDP/Cux transcription factor. Mol Cell 2004;14:207-19.
28. Menard R, Carmona E, Takebe S, Dufour E, Plouffe C, Mason P, et al. Autocatalytic processing of recombinant human procathepsin L. J Biol Chem 1998;273:4478-84.
29. Greidinger EL, Casciola-Rosen L, Morris SM, Huffman RW, Rosen A. Autoantibody recognition of distinctly modified forms of the U1-70-kd antigen is associated with different clinical disease manifestations. Arthritis Rheum 2000;43:881-8.
30. Jun JB, Kuechle M, Harlan JM, Elkon KB. Fibroblast and endothelial apoptosis in systemic sclerosis. Curr Opin Rheumatol 2003;15:756-60.
31. Cirman T, Oresik K, Mazovec GD, Turk V, Reed JC, Myers RM, et al. Selective disruption of lysosomes in HeLa cells triggers apoptosis mediated by cleavage of Bid by multiple papain-like lysosomal cathepsins. J Biol Chem 2004;279:3578-87.
32. Biggs JR, Yang J, Gulberg U, Muchardt C, Yaniv M, Kraft SA. The human brm protein is cleaved during apoptosis: the role of cathepsin G. Proc Natl Acad Sci U S A 2001;98:3814-9.
33. Schotte P, Declercq W, van Huffel S, Vandenabeele P, Bevaert R. Non-specific effects of methyl ketone peptide inhibitors of caspases. FEBS Lett 1999;442:117-21.
34. Zheng X, Chou PM, Mirkin BL, Rebbaa A. Senescence-initiated reversal of drug resistance: specific role of cathepsin L. Cancer Res 2004;64:1773-80.
35. Ebert DH, Kopecky-Bromberg SA, Dermody TS. Cathepsin B is inhibited in mutant cells selected during persistent reovirus infection. J Biol Chem 2004;279:3837-51.
36. Sheriff A, Gaipl US, Voll RE, Kalden JR, Herrmann M. Apoptosis and systemic lupus erythematosus. Rheum Dis Clin North Am 2004;30:505-27.
37. Navratil JS, Sabatine JM, Ahearn JM. Apoptosis and immune responses to self. Rheum Dis Clin North Am 2004;30:193-212.
38. Gaipl US, Beyer TD, Heyder P, Kuenkele S, Bottcher A, Voll RE, et al. Cooperation between C1q and DNase I in the clearance of necrotic cell-derived chromatin. Arthritis Rheum 2004;50:640-9.
39. Napirei M, Wulf S, Mannherz HG. Chromatin breakdown during necrosis by serum Dnase1 and the plasminogen system. Arthritis Rheum 2004;50:1873-83.
40. Bondanza A, Zimmermann VS, Dell'Antonio G, Cin ED, Balestrieri G, Tincani A, et al. Requirement of dying cells and environmental adjuvants for the induction of autoimmunity. Arthritis Rheum 2004;50:1549-60.
41. Kuwana M, Feghali CA, Medsger TA Jr, Wright TM. Autoreactive T cells to topoisomerase I in monozygotic twins discordant for systemic sclerosis. Arthritis Rheum 2001;44:1654-9.